Literature DB >> 21123453

A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.

Nunzio Iraci1, Daniel Diolaiti, Antonella Papa, Antonio Porro, Emanuele Valli, Samuele Gherardi, Steffi Herold, Martin Eilers, Roberto Bernardoni, Giuliano Della Valle, Giovanni Perini.   

Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood. One important factor that predicts a favorable prognosis is the robust expression of the TRKA and p75NTR neurotrophin receptor genes. Interestingly, TRKA and p75NTR expression is often attenuated in aggressive MYCN-amplified tumors, suggesting a causal link between elevated MYCN activity and the transcriptional repression of TRKA and p75NTR, but the precise mechanisms involved are unclear. Here, we show that MYCN acts directly to repress TRKA and p75NTR gene transcription. Specifically, we found that MYCN levels were critical for repression and that MYCN targeted proximal/core promoter regions by forming a repression complex with transcription factors SP1 and MIZ1. When bound to the TRKA and p75NTR promoters, MYCN recruited the histone deacetylase HDAC1 to induce a repressed chromatin state. Forced re-expression of endogenous TRKA and p75NTR with exposure to the HDAC inhibitor TSA sensitized neuroblastoma cells to NGF-mediated apoptosis. By directly connecting MYCN to the repression of TRKA and p75NTR, our findings establish a key pathway of clinical pathogenicity and aggressiveness in neuroblastoma.
© 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123453     DOI: 10.1158/0008-5472.CAN-10-2627

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Epigenetic reprogramming of Myc target genes.

Authors:  Stefano Amente; Luigi Lania; Barbara Majello
Journal:  Am J Cancer Res       Date:  2011-02-06       Impact factor: 6.166

Review 2.  Family matters: How MYC family oncogenes impact small cell lung cancer.

Authors:  Johannes Brägelmann; Stefanie Böhm; Matthew R Guthrie; Gurkan Mollaoglu; Trudy G Oliver; Martin L Sos
Journal:  Cell Cycle       Date:  2017-07-24       Impact factor: 4.534

3.  Redefining functional MYCN gene signatures in neuroblastoma.

Authors:  Jason Matthew Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-08       Impact factor: 11.205

Review 4.  MYC cofactors: molecular switches controlling diverse biological outcomes.

Authors:  Stephen R Hann
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-17       Impact factor: 6.915

5.  Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.

Authors:  Presha Rajbhandari; Gonzalo Lopez; Claudia Capdevila; Beatrice Salvatori; Jiyang Yu; Ruth Rodriguez-Barrueco; Daniel Martinez; Mark Yarmarkovich; Nina Weichert-Leahey; Brian J Abraham; Mariano J Alvarez; Archana Iyer; Jo Lynne Harenza; Derek Oldridge; Katleen De Preter; Jan Koster; Shahab Asgharzadeh; Robert C Seeger; Jun S Wei; Javed Khan; Jo Vandesompele; Pieter Mestdagh; Rogier Versteeg; A Thomas Look; Richard A Young; Antonio Iavarone; Anna Lasorella; Jose M Silva; John M Maris; Andrea Califano
Journal:  Cancer Discov       Date:  2018-03-06       Impact factor: 39.397

6.  The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

Authors:  Swapan K Ray
Journal:  For Immunopathol Dis Therap       Date:  2016

7.  Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Authors:  Belamy B Cheung; Owen Tan; Jessica Koach; Bing Liu; Michael S Y Shum; Daniel R Carter; Selina Sutton; Sela T Po'uha; Louis Chesler; Michelle Haber; Murray D Norris; Maria Kavallaris; Tao Liu; Geraldine M O'Neill; Glenn M Marshall
Journal:  Mol Oncol       Date:  2015-04-29       Impact factor: 6.603

Review 8.  The abbreviated pluripotent cell cycle.

Authors:  Kristina Kapinas; Rodrigo Grandy; Prachi Ghule; Ricardo Medina; Klaus Becker; Arthur Pardee; Sayyed K Zaidi; Jane Lian; Janet Stein; Andre van Wijnen; Gary Stein
Journal:  J Cell Physiol       Date:  2013-01       Impact factor: 6.384

9.  Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Authors:  Linda J Valentijn; Jan Koster; Franciska Haneveld; Rachida Ait Aissa; Peter van Sluis; Marloes E C Broekmans; Jan J Molenaar; Johan van Nes; Rogier Versteeg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

10.  MYCN Silencing by RNAi Induces Neurogenesis and Suppresses Proliferation in Models of Neuroblastoma with Resistance to Retinoic Acid.

Authors:  Ruhina Maeshima; Dale Moulding; Andrew W Stoker; Stephen L Hart
Journal:  Nucleic Acid Ther       Date:  2020-04-02       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.